Legend Biotech Announces Submission To European Medicines Agency For Expanded Use Of CARVYKTI
Portfolio Pulse from Benzinga Newsdesk
Legend Biotech has submitted an application to the European Medicines Agency (EMA) for the expanded use of CARVYKTI, a CAR T-cell therapy for multiple myeloma patients.
May 25, 2023 | 12:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Legend Biotech's submission to the EMA for expanded use of CARVYKTI may lead to increased revenue and market share if approved.
The submission to the EMA for expanded use of CARVYKTI directly involves Legend Biotech. If approved, it could lead to increased revenue and market share for the company, positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100